News

Tarlatamab for Small Cell Lung Cancer: How DLL3 Immunotherapy Is Changing Treatment

Learn how tarlatamab targets DLL3, the evidence from the DeLLphi clinical trials, and the current Australian access pathway for relapsed small cell lung cancer.

Small Cell Lung Cancer: Why Tarlatamab Marks a New Era in Treatment

After decades of limited progress, treatment for small cell lung cancer (SCLC) is beginning to change. Tarlatamab, the first Delta-like ligand 3 (DLL3)-targeted bispecific T-cell engager, has demonstrated improved survival in patients whose cancer has progressed after platinum-based chemotherapy and represents a fundamentally different approach to immunotherapy. Although it is not yet PBS listed in Australia, it is reshaping how researchers think about treating relapsed SCLC.

What is SCLC?

SCLC accounts for approximately 15% of all lung cancers. It grows rapidly, spreads early and is strongly associated with smoking. It is staged as either ‘limited stage’, where the cancer is confined to one general area of the chest and can usually be treated with radiotherapy to the chest as well as chemotherapy; or ‘extensive stage’, where the cancer has spread more widely, either elsewhere in the chest or to other parts of the body. Extensive stage may also be described as Stage IV disease. 

SCLC has lacked obvious molecular targets that medicines could exploit, and for years treatment has consisted of platinum-based chemotherapy, with radiation therapy for limited-stage disease.

Immune Checkpoint Inhibitors in SCLC

The striking feature of SCLC is that it often responds very well at first. Historically, platinum-etoposide produced response rates of around 70–80%. The problem was durability: median progression-free survival was only about five months and median overall survival about 10 months.

After many immune checkpoint inhibitors showed early promise, they failed to show significance in Phase III trials. It was in the IMpower133 and CASPIAN trials that chemo-immunotherapy was established as first-line treatment in ES-SCLC, adding atezolizumab or durvalumab to platinum-etoposide and then continuing immunotherapy as maintenance. In both studies, the addition of immunotherapy extended median overall survival by approximately two to three months, a relatively modest improvement.

More recently, the ADRIATIC trial extended the role of immunotherapy into limited-stage SCLC, with consolidation durvalumab after chemoradiotherapy increasing median overall survival from 33.4 to 55.9 months. Together, these studies established that the immune system could be harnessed against SCLC. However, in ES-SCLC the survival gains remained modest and most patients still experienced disease progression.

Timeline of major advances in small cell lung cancer treatment from the 1970s to 2026, showing the introduction of platinum chemotherapy, thoracic radiotherapy, prophylactic cranial irradiation, first-line immunotherapy with atezolizumab and durvalumab, lurbinectedin, consolidation durvalumab, tarlatamab, and emerging therapies including bispecifics, trispecifics, ADCs and radiopharmaceuticals.
Evolution of SCLC therapeutic landscape: through the ages. ADC, antibody-drug conjugate; ES, extensive stage; L, line; LS, limited stage; SCLC, small cell lung cancer. Image courtesy of Arya 2026 et al. DOI: 10.1200/EDBK-26-524964

How is SCLC Treated After Progression?

Patients whose cancer recurs after a longer interval following platinum treatment are often described as having ‘platinum-sensitive disease’. Earlier relapse is considered platinum-resistant, while progression during first-line treatment is described as refractory disease. These categories are not absolute and clinicians may use them more flexibly in practice, but they reflect an important biological and clinical difference in how SCLC behaves after initial therapy.

Historically, treatment choices after relapse have been limited. Chemotherapies such as topotecan, platinum re-challenge in selected patients and other agents have provided options, but the magnitude and duration of benefit have generally been modest.

A diagram of a lung tumour cell is brought into close proximity of a T cell through tarlatamab bringing both T cell and tumour cell forming a 'bridge'.
Tarlatamab is a bispecific antibody that uses uses DLL3 to bind to the T cell, bringing the tumour cell and T cell into closer proximity and encouraging T cell-mediated lysis. Adapted from Abdelmoaty et al (2025)

A Different Strategy: Targeting DLL3

Delta-like ligand 3 (DLL3) is associated with the neuroendocrine biology of SCLC and is expressed on the surface of most SCLC tumour cells. Importantly, it is largely absent from the surface of normal cells; where DLL3 is present in normal tissues, it is generally located inside the cell rather than exposed on the cell surface. This makes DLL3 an attractive target for therapies designed to distinguish tumour cells from normal tissue.

Tarlatamab is a bispecific T-cell engager designed to exploit this difference. One part of tarlatamab binds to DLL3 on the SCLC cell. The other binds to CD3 on a T-cell. By physically bringing the two cells together, tarlatamab promotes T-cell activation and direct killing of the cancer cell.

This mechanisms of action differs from checkpoint inhibitors such as atezolizumab or durvalumab. Checkpoint inhibitors remove inhibitory signals that can restrain an existing immune response. T-cell engagers instead redirect T-cells directly towards a tumour-associated target.  That distinction is one reason tarlatamab is generating such excitement in SCLC. For the first time, a treatment directed against a new biological target in SCLC has demonstrated a substantial survival advantage over conventional second-line chemotherapy.

What Did the DeLLphi Trials Show?

Early clinical studies established that targeting DLL3 with tarlatamab could produce responses in patients with heavily pretreated SCLC. The phase II DeLLphi-301 study helped establish the activity of tarlatamab in relapsed disease and supported its initial regulatory development.

The more important change came with the phase III DeLLphi-304 trial, which directly compared tarlatamab with standard chemotherapy in 509 patients whose SCLC had progressed during or after platinum-based treatment. Median overall survival was 13.6 months with tarlatamab compared with 8.3 months with chemotherapy, corresponding to a 40% reduction in the risk of death. Grade 3 or higher adverse events were also less frequent with tarlatamab than chemotherapy (54% versus 80%).

The DeLLphi programme is now examining whether DLL3-directed T-cell engagement could be used as maintenance treatment after first-line chemo-immunotherapy, incorporated earlier into first-line therapy, or used after chemoradiotherapy in limited-stage disease. For ES-SCLC in particular, the attraction of moving treatment earlier is clear. There is substantial attrition between treatment lines: some patients deteriorate rapidly after progression and never reach later-line treatment. Introducing a more active therapy earlier could therefore allow more patients to receive it.

Early studies of tarlatamab in the first-line and maintenance settings have produced encouraging signals, but these are not yet practice-changing results. Phase III trials are needed to establish whether the apparent benefits seen in earlier-phase studies translate into longer survival in broader patient populations. Other DLL3-targeting T-cell engagers in development include obrixtamig, gocatamig and alveltamig. Early studies have shown activity across several agents, although cross-trial comparisons are difficult and their relative efficacy, safety and future roles remain uncertain.

Diagram showing where DeLLphi tarlatamab trials fit within limited-stage, extensive-stage and relapsed small cell lung cancer treatment pathways, including DeLLphi-306, DeLLphi-305, DeLLphi-304 and DeLLphi-301.

Can We Predict Who Will Benefit From Tarlatamab?

Although DLL3 provides the target for tarlatamab, simply measuring DLL3 expression in a tumour has not yet provided a reliable way to predict who will respond. In early analyses, conventional DLL3 immunohistochemistry was not clearly predictive, and responses have also been observed in patients whose tumour samples were classified as DLL3-negative.

Researchers are therefore exploring other approaches. One possibility is measuring DLL3 on circulating tumour cells. Early studies suggest that changes in DLL3 expression during treatment may also provide clues about resistance, although these findings require further validation.

Identifying which patients derive the greatest and most durable benefit remains an important research priority as DLL3-targeted therapies move into earlier treatment settings.

What is the Current Australian Access Position for Tarlatamab?

Tarlatamab is provisionally approved by the Therapeutic Goods Administration (TGA) in Australia for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy. However, it is not currently listed on the Pharmaceutical Benefits Scheme (PBS).

At its March 2026 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) considered an application for tarlatamab in patients with ES-SCLC only, whose disease had progressed on or after platinum-based chemotherapy. This would position tarlatamab mainly as a second-line treatment, with some use in later lines.

The PBAC agreed that this was an appropriate place for tarlatamab in the treatment pathway and recognised the substantial unmet need for more effective therapies in relapsed ES-SCLC. It also accepted that the DeLLphi-304 evidence suggested improvements in progression-free survival and overall survival compared with standard chemotherapy.

However, the PBAC did not recommend listing at that meeting, with the principal feedback being cost-effectiveness. The PBAC advised that these issues could potentially be addressed through an early re-entry submission. This means the March 2026 decision should not be interpreted as a rejection of tarlatamab’s clinical value, but as an unresolved reimbursement decision.

In the meantime, access may be available through clinical trials or other managed access pathways in selected circumstances. Patients interested in tarlatamab should discuss eligibility with their treating medical oncologist.

What are CRS and ICANS?

Tarlatamab has a different toxicity profile from chemotherapy and conventional checkpoint inhibitors because it activates T cells directly.

The two adverse events of greatest clinical importance are:

  • cytokine release syndrome (CRS)
  • immune effector cell-associated neurotoxicity syndrome (ICANS)

These reactions occur most often during the first one or two doses, when the immune system is first exposed to tarlatamab. Patients receive a lower first dose before escalating to the full treatment dose, with close monitoring during the initial treatment period when CRS and ICANS are most likely to occur.

Cytokine release syndrome

CRS is an inflammatory reaction caused by rapid immune-cell activation and the release of cytokines into the bloodstream.

Symptoms can include:

  • fever and chills
  • fatigue
  • low blood pressure
  • low oxygen levels
  • rapid heart rate
  • nausea or headache.

Most CRS reported with tarlatamab has been mild to moderate, but severe and potentially life-threatening reactions can occur. 

Immune effector cell-associated neurotoxicity syndrome

ICANS is a neurological reaction associated with immune-cell activation.

It may present as:

  • confusion or disorientation
  • difficulty speaking or finding words
  • altered handwriting
  • drowsiness
  • tremor
  • weakness
  • seizures in severe cases.

Patients are assessed using structured neurological checks that test functions such as orientation, naming and ability to follow commands.

CRS occurs predominantly during the early treatment period, particularly following the first and second step-up doses, and becomes much less common with subsequent treatment. ICANS is less common and may occur later, so neurological symptoms remain important to recognise beyond the initial dosing period.

Below is a presentation delivered by A/Prof Surein Arulananda at the TOGA ASm 2026, where he shares practical, real-world experience managing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients treated with the T-cell engager tarlatamab.

References

1.Abdelmoaty, Ahmed & Badran, Ahmed. (2025). Pharmacokinetics and pharmacodynamics of Tarlatamab, DLL3-Targeted FDA-approved Bispecific T-Cell Engager. Asia-Pacific Journal of Pharmacotherapy & Toxicology. 44-52. DOI: 10.32948/ajpt.2025.04.15.

2.Ahn et al (2023) Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer (DeLLphi-301) N Engl J Med 389:2063. DOI: 10.1056/NEJMoa2307980

3.Arya Y, Dyer P, Hegi-Johnson F, Reguart N, Manochakian R (2026) Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances. Am Soc Clin Oncol Educ Book 46:e524964. DOI: 10.1200/EDBK-26-524964

4.Kalemkerian et al (2025) Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update J Clin Oncol 43, 101-105 DOI: 10.1200/JCO-24-0224

5.Mountzios et al (2025) Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy (DeLLphi-304) N Engl J Med 393:349 DOI: 10.1056/NEJMoa2502099

6.Paulsson  K et al (2025) Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study 26:1300  https://doi.org/10.1016/S1470-2045(25)00480-2

7.Public Summary Document – March 2026 PBAC Meeting Tarlatamab

Share this

Facebook
Twitter
LinkedIn
Two years ago, thanks to the generosity of our philanthropic donors, TOGA awarded the first ever Inspirational Research Grants. Read their final achievements.
Consumer involvement in research changed the DYNAMALK lung cancer study, broadening its design and making the research more relevant to people with ALK+ NSCLC.
Learn how antibody-drug conjugates (ADCs) work in lung cancer, the major clinical trials, emerging biomarkers and how these targeted therapies are changing treatment.
Bispecific antibodies bind two different targets at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Occasionally, there will be one presentation that stands out for a different reason. See why Dr Prem Ram's talk changed the game.
Consumer involvement can strengthen research design and grant applications. This practical guide explains when to involve consumers, what to ask, how to document their influence
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.